Patents by Inventor Kenneth Charles Fang
Kenneth Charles Fang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11193935Abstract: The present invention provides methods for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. The present invention also provides compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).Type: GrantFiled: August 18, 2017Date of Patent: December 7, 2021Assignee: Biodesix, Inc.Inventors: Paul Edward Kearney, Kenneth Charles Fang, Xiao-Jun Li, Clive Hayward
-
Patent number: 10802027Abstract: Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).Type: GrantFiled: May 5, 2017Date of Patent: October 13, 2020Assignee: Biodesix, Inc.Inventors: Paul Edward Kearney, Kenneth Charles Fang, Xiao-Jun Li, Clive Hayward
-
Patent number: 10338074Abstract: Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).Type: GrantFiled: February 23, 2016Date of Patent: July 2, 2019Assignee: Biodesix, Inc.Inventors: Paul Edward Kearney, Kenneth Charles Fang, Xiao-Jun Li, Clive Hayward
-
Publication number: 20180067119Abstract: Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).Type: ApplicationFiled: October 18, 2017Publication date: March 8, 2018Inventors: Paul Edward KEARNEY, Kenneth Charles FANG, Xiao-Jun LI, Clive HAYWARD, Douglas SPICER
-
Publication number: 20180059113Abstract: Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).Type: ApplicationFiled: May 5, 2017Publication date: March 1, 2018Inventors: Paul Edward KEARNEY, Kenneth Charles Fang, Xiao-Jun Li, Clive Hayward
-
Publication number: 20180011099Abstract: The present invention provides methods for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. The present invention also provides compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).Type: ApplicationFiled: August 18, 2017Publication date: January 11, 2018Inventors: Paul Edward Kearney, Kenneth Charles Fang, Xiao-Jun Li, Clive Hayward
-
Patent number: 9588127Abstract: Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).Type: GrantFiled: October 29, 2015Date of Patent: March 7, 2017Assignee: Integrated Diagnostics, Inc.Inventors: Paul Edward Kearney, Kenneth Charles Fang, Xiao-Jun Li, Clive Hayward
-
Publication number: 20160169900Abstract: Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).Type: ApplicationFiled: February 23, 2016Publication date: June 16, 2016Inventors: Paul Edward Kearney, Kenneth Charles Fang, Xiao-Jun Li, Clive Hayward
-
Publication number: 20160161493Abstract: The present invention provides methods for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. The present invention also provides compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).Type: ApplicationFiled: February 11, 2016Publication date: June 9, 2016Inventors: Paul Edward Kearney, Kenneth Charles Fang, Xiao-Jun Li, Clive Hayward
-
Patent number: 9304137Abstract: Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).Type: GrantFiled: February 25, 2013Date of Patent: April 5, 2016Assignee: Integrated Diagnostics, Inc.Inventors: Paul Edward Kearney, Kenneth Charles Fang, Xiao-Jun Li, Clive Hayward
-
Patent number: 9297805Abstract: The present invention provides methods for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. The present invention also provides compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).Type: GrantFiled: July 25, 2014Date of Patent: March 29, 2016Assignee: Integrated Diagnostics, Inc.Inventors: Paul Edward Kearney, Kenneth Charles Fang, Xiao-Jun Li, Clive Hayward
-
Publication number: 20160047820Abstract: Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).Type: ApplicationFiled: October 29, 2015Publication date: February 18, 2016Inventors: Paul Edward Kearney, Kenneth Charles Fang, Xiao-Jun Li, Clive Hayward
-
Patent number: 9221889Abstract: The present application provides biligand and triligand protein-catalyzed capture (PCC) agents that specifically bind VEGF, as well as the use of these capture agents as detection, diagnosis, and treatment agents.Type: GrantFiled: January 7, 2014Date of Patent: December 29, 2015Assignee: INDI MOLECULAR, INC.Inventors: Suresh Mark Pitram, Heather Dawn Agnew, Tsun Yin Lai, Rosemary Dyane Rohde, Paul Edward Kearney, Scott Law, Kenneth Charles Fang
-
Patent number: 9201044Abstract: Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).Type: GrantFiled: December 21, 2012Date of Patent: December 1, 2015Assignee: Integrated Diagnostics, Inc.Inventors: Paul Edward Kearney, Kenneth Charles Fang, Xiao-Jun Li, Clive Hayward
-
Publication number: 20150031065Abstract: The present invention provides methods for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. The present invention also provides compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).Type: ApplicationFiled: July 25, 2014Publication date: January 29, 2015Inventors: PAUL EDWARD KEARNEY, Kenneth Charles Fang, Xiao-Jun Li, Clive Hayward
-
Publication number: 20140256630Abstract: The present application provides biligand and triligand protein-catalyzed capture (PCC) agents that specifically bind VEGF, as well as the use of these capture agents as detection, diagnosis, and treatment agents.Type: ApplicationFiled: January 7, 2014Publication date: September 11, 2014Applicant: Indi Molecular, Inc.Inventors: Suresh Mark PITRAM, Heather Dawn AGNEW, Tsun Yin LAI, Rosemary Dyane ROHDE, Paul Edward Kearney, Scott LAW, Kenneth Charles FANG
-
Publication number: 20130230877Abstract: Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g.Type: ApplicationFiled: February 25, 2013Publication date: September 5, 2013Applicant: INTEGRATED DIAGNOSTICS, INC.Inventors: Paul Edward Kearney, Kenneth Charles Fang, Xiao-Jun Li, Clive Hayward